Beta Bionics preliminary Q4 2025 net sales ≥$32M, up >56% YoY; installed base >35K

Beta Bionics, Inc.

2025-FY EPS reported -$1.81 revenue$100,251,000

Net sales expected ≥$32.0M, up >56% from $20.4M in Q4 2024.
DME channel net sales ≥$22.3M (+23% YoY); PBP channel ≥$9.7M (+308% YoY).
Installed customer base ≥35,000 users (+128% YoY); new patient starts ≥5,581 (+36% YoY).
~69% of new starts from multiple daily injections; 25-30% are type 2 diabetes patients.
Full Q4 and FY 2025 results to be reported Feb 17, 2026; conference call scheduled.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.